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ABSTRACT 
Chorangioma (CA), although, is the most common non-trophoblastic, vascular, tumor-like-
lesion of the placenta with incidence approximately 0.5-1% of all examined placentas, the 
specific etiology and genetic background of these lesions is still poorly understood. 
However, an increased incidence of CAs has been reported in pregnancies occurring at high 
altitudes and in relation to the in utero hypoxic status (preeclampsia, multiple gestation). 
Thus, CAs are suggested to be hypoxia-induced reactive vascular hyperplasias rather than 
true tumors, although this theory has not been supported by systemic genetic studies, so far. 
In contrast, the occasional reports of recurrence of CA suggest that genetic factors may play 
also role in the pathogenesis of these lesions. Further, infantile hemangioma (IH) shares 
various histochemical and genetic characteristics with placental endothelial cells; notably, a 
predictable life cycle of initial proliferation followed by apoptotic involution similarly to 
that of the placenta. These findings suggest the possibility that the placenta could be the 
origin site of IH. 
 
Our first and second studies characterized 170 CA cases morphologically and clinically 
providing evidence that CAs are associated with an increased rate of hypoxia related 
placental morphological changes and more adverse clinical outcome in singleton 
pregnancies compared with multiple pregnancies. 
 
Our cohort of CAs demonstrated a high incidence of preeclampsia, which could be an 
invaluable information for clinical placental diagnostics and might lead to a possible 
recognition of CAs as potential morphologic indicator for placental hypoxia. 
 
The third study of genetic background of CA analyzed eight large CAs using the array 
comparative genomic hybridization method and revealed no pathogenic copy number 
variants in the CA samples compared with either standard control DNA or unaffected 
placenta DNA from the same individual. This lack of association in our pilot study could 
support a non-tumorous, non-genetic origin of the CAs; however, additional genetic studies 
of larger sample sets are required to fully exclude a possible genetic contribution.  
 
In our fourth study, we investigated the co-existence of CA and IH using a questionnaire 
answered by the parents and failed to demonstrate any correlations between CAs and IH. 
Furthermore, the occurrence of multiple pregnancies or preeclampsia was not associated 
with an increased incidence of IH. The latter could be explained by the fact that 
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1 BACKGROUND     
1.1 CHORANGIOMA (CA) 
1.1.1 Introduction 
Chorangioma (CA) is the most common non-trophoblastic, vascular, tumor-like-lesion of 
the placenta, first described by John Clarke in 1789 (1). In the early stage of pregnancy, 
development of the normal placenta begins with vasculogenesis (the de novo formation of 
blood vessels from progenitor cells) and formation of precursor villi, where endothelial 
progenitor cells differentiate into angioblastic cords (2,3,4). These precursor villi form later 
the stem villi. The early placental development is influenced by several factors, including 
local low oxygen tensions, high level of growth factor receptors and their ligands (in 
particular, vascular endothelial growth factor (VEGF), and placental growth factor (PlGF) 
(2,5,6). Low oxygen environment is result of extravillous trophoblast invasion into the 
decidua, occluding spiral arteries and restricting blood flow into the intervillous space (7). 
Further, the capillaries are formed by angiogenesis, where new vessels arise through 
branching of preexisting vessels and give rise to the immature intermediate villi (2,3). 
Noteworthy, hypoxia is the main pathophysiologic stimulus for angio-and vasculogenesis (8). 
Later, the process transforms to a non-branching linear growth because of high oxygen 
tension, as spiral arteries become patent and blood flow increases, and low VEGF levels, to 
form mature intermediate and finally terminal villi (2,5,7). CA is a lesion of capillary 
dysvasculogenesis and they are usually found at the placental margin or immediately below 
the chorionic plate, which are the most poorly perfused areas of the placenta (2,3). Therefore, 
several possibilities for pathogenesis are suggested, including: inception early in gestation, 
origin from primary stem villi, or induced by hypoxia (3). Origin early in gestation seems 
unlikely in view of the lack of reported cases in early pregnancies (3). Ultrastructural studies 
support the origin from primary stem villi (3). An increased incidence of CAs has been 
reported in pregnancies occurring at high altitudes and in relation to maternal smoking (2,3). 
Consequently, it has been suggested that CAs may be hypoxia-induced vascular proliferations 
influenced by multiple growth factors and subsequently associated to the pathological 
conditions during pregnancy rather than to abnormal embryogenesis (1). Thus, CAs are 
hypothesized to be reactive vascular hyperplasias or hamartomas rather than true tumors, 
although this hypothesis has not been supported by systemic genetic studies so far (3,9). 
 
1.1.2 Incidence 
The incidence of CA is reported approximately 0.5 and 1% of all examined placentas (1,10). 
It varies in different reports about different study cohorts. Guschmann et al. performed a 
retrospective study on 22439 supposedly unselected multiple and singleton placentas and 
found 136 cases of CA, with an incidence of 0.61% (11,12). Wou et al. examined 
retrospectively 14725 singleton placentas and found 23 cases with CA; the incidence was 
14 
0.16% (11,13). Ogino et al reported 36 cases of CA in a cohort of 7062 examined placentas, 
incidence of CA was 0.51% (3). 
Most CAs are incidental findings measuring less than 5 mm (14). Lesions up to 40 mm in 
diameter are usually asymptomatic and the clinical significance of microscopic CAs remains 
unknown (14). Large CAs measuring more than 4–5 cm, with an incidence of 1:3500 to 
1:9000 (0.29%–0.11%) births (1,11,13,15,16,17,18,19,20). CAs are supplied by the fetal 
circulation and are often associated with maternal and fetal complications including 
polyhydramnios, antepartum hemorrhage with premature placental detachment, preterm 
labor, fetal anemia, thrombocytopenia, non-immune fetal hydrops, intrauterine fetal growth 
restriction (IUGR) and increased perinatal mortality (11,14,21,22,23,24,25,26).  The overall 
mortality rate associated with large CAs is about 20-40% (6,7,87,89,91). Although the 
underlying pathophysiology for these complications has not been clearly elucidated, several 
mechanisms explaining the pathogenesis of the complications are proposed. For example, a 
chronic arteriovenous shunting in the tumor can affect the fetal circulation by increasing the 
venous return to the heart and causing the development of fetal congestive heart failure, 
which could be suspected by the presence of hydrops (11,23,24,25,30,31). The sequestration 
of red blood cells and platelets within the tumor and thrombocytic microangiopathy are, in 
turn, the main hypotheses, that could explain the pathogenesis of anemia and 
thrombocytopenia (11,20,23,24,25,31). Further, polyhydramnios has been associated to 
increased production of urine due to the hyperdynamic fetal circulation linked either to 
shunting of the blood in CA or fetal anemia (19,20). In addition, the transudation of fluid 
from CA surface may contribute to the accumulation of amniotic fluid (19,20).  
The presence of CA correlates with increased maternal age and has been associated with 
HELLP (hemolytic anemia, elevated liver enzymes and low platelet count) syndrome, 
preeclampsia, multiple gestation and preterm birth (3,11,23). CAs can be usually observed 
from the second trimester of pregnancy (3,11).  
It is reported that CA occur more often in the female fetuses (6,12,13,32). Guschmann et al. 
analyzed 136 cases of CA and the female fetus was related in 72.2% of pregnancies (11,12). 
Comparably, Wou et al. reported that in 16 out of 23 (69.6%) CA cases female neonates were 
involved (11,13). 
An increased incidence of CA has been described also in pregnancies at high altitude (above 
3600 m) where the most notable factor of all specific environmental conditions is the 
prevailing hypobaric hypoxia (2,3,11). Hypoxia is believed to be a major stimulus for 
placental angiogenesis (2,33,34). The placenta at high altitude is capable to increase its 
oxygen-transporting capacity between mother and fetus through the reduction in the thickness 
of the vasculosyncytial villous membranes as a result of adaptation to the hypobaric hypoxia 
(34,35). Of interest, over-expression of angiogenic cytokines, such as VEGF, which is known 
to be up-regulated by hypoxia, may lead to excessive proliferation of endothelial cells and 
formation of CA (11,35).  
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The recurrence of CA in subsequent pregnancies has been reported in occasional studies, 
suggesting that genetic predisposition may also play a role in the pathogenesis of CA 
(2,11,36). 
 
1.1.3 Gross morphology 
CAs are usually single, but multiple lesions can be found after thorough morphological 
examination of the placenta (1,37). They may be small, a few millimeters in diameter, or may 
form large masses, even up to 1500 g (1,2). Large CAs are most commonly seen as nodular 
lesions bulging on the fetal surface of the placenta (1,2,23) (Figure 1.). Occasionally they 
may be attached to the placenta only by a vascular pedicle (1,2). Most CAs are small, within 
the placental substance and not visible externally, hence to be detected the placenta must be 
systematically sliced (1). The small intraplacental lesions are usually round and well 
demarcated from the surrounding normal placental parenchyma (1). The cut surface of CAs 
may vary from red to white and is usually smoother and firmer than surrounding placental 
tissue (1). They may resemble fibromas, when a large stromal component is present (2). The 








Figure 1. Gross morphology of large CAs (arrows, A, B). 
 
1.1.4 Microscopic features 
Most CAs have histological appearance analogous to hemangiomas at other body sites 
(hemangioma of the placenta) (1,2,3). CA is a well-demarcated nodular mass composed of 
numerous capillary vascular channels supported by a perivascular stroma containing 
fibroblasts, macrophages and scanty fibrous tissue (1,2,3,38) (Figure 2.). They are surrounded 
by a layer of trophoblast (2,3). The stromal component may be predominant with very few 
vessels and may show degenerative changes such as myxoid changes, hyalinization, necrosis, 
calcification, which may complicate and confuse the histological appearance (1). Mitotic 
figures may be seen in some cases of CA and they may be associated with some degree of 
A B 
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atypia in endothelial or stromal cells; there is, however, no evidence that CAs behave as 
malignant tumors (1,30). Immunohistochemically CA cells show positive expression for 
CD31, CD34, factor VIII, GLUT 1 (glucose transporter protein isoform 1) and cytokeratin 18 
















Figure 2. Histological features of large (A) and microscopic CA (B), hem.-eos, 50x; nodular 
structure and proliferation of capillary blood vessels in CA (C), hem.-eos. 100x, GLUT 1 
positive staining of endothelial cells and erythrocytes in CA (D), 200x. 
 
1.1.5 Molecular background 
Very little is known about the genetic background of CAs, however, the occasional reports of 
recurrence of CA suggest that genetic factors may play role in the pathogenesis of these 
lesions (2,11,36). Very few cytogenetic data have been reported regarding CA in the 
literature. Miliaras et al reported deletions at 2q13 and 7p21.1 in CA and hepatic cavernous 
hemangioma tissue presented in the same patient (40,41). Wuster et al found a chromosomal 
translocation at 2q-;15q+ in dizygous twin girl with mental deficiency and marked placental 
chorangiomatosis (42). Kim et al, however, reported a normal karyotype in another case of 
CA (43).  
C D 
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1.1.6 Diagnosis  
Small CAs are usually found only after careful morphological examination of the placenta 
(15,26). Large CAs, however, are in most cases found prenatally during routine ultrasound 
examination and diagnosis is confirmed by histopathologic examination (15,22,23). Gray-
scale ultrasound shows hypo-or hyperechogenic well-circumscribed mass, which is clearly 
different from surrounding placental tissue (26,44,45). The ultrasonographic echo-texture of 
CA is usually changing during pregnancy due to the degenerative changes (calcification, 
necrosis) in the tumor (23,44). By color Doppler imaging vascular nature with blood flow 
within the lesion can be confirmed and the relation to fetal circulation elucidated 
(29,31,44,46). Feeding vessels of the lesion usually show same pulsatile flow as that of 
umbilical artery arteriovenous shunting in the tumor, however, can cause low resistance flow 
(30). Routine ultrasound examinations, including gray-scale and color Doppler 
ultrasonagraphy, plays an important role in the prenatal diagnosis and monitoring of large 
CAs (15,44). Due to the potential risk for complications caused by the CA, early diagnosis, 
close prenatal surveillance, and intrauterine treatment can be implemented to prevent fetal 








Figure 3. Gray-scale ultrasound image of well-demarcated large CA at gestational age 34+5 
weeks (A); color Doppler image, same case (B). 
 
1.1.7 Treatment 
Approximately 50% of large CAs develop complications requiring clinical intervention (48). 
Arterio-venous shunting in the large CA can create significant hemodynamic disturbances in 
fetal circulation and result in fatal complications (48). Thus, the treatment of CAs should be 
targeted to diminish or arrest the blood flow in the CA (29,48). Eleven cases of fetoscopy-
guided laser photocoagulation of surface feeding vessels and 7 cases of antenatal 
embolization of the tumor feeding vessels using alcohol, microcoil or cyanoacrylate have 
been reported regarding attempts to treat large CAs (10,16,19,28,48,49,50). Based on 
reported treated cases, successful result of the clinical intervention is achieved, when CA is 
A B 
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located further away from the umbilical cords insertion, so that the main circulation of the 
tumor is not directly dependent on the umbilical cord. (10) 
Also, endoscopy-guided surgical ligation of vessels with bipolar electrocautery and 
ultrasound-guided percutaneous interstitial laser ablation have been described as therapeutic 
methods for large CAs (28,31,48). 
Complications secondary to large CAs as polyhydramnios and fetal anemia have been treated 
with therapeutic amnioreduction, which is the least invasive prenatal intervention option, and 
intrauterine blood transfusion (18,28,29,30,45,48). 
Padys et al suggested a non-selective beta-blocker, propranolol, which has been used to treat 
fetal tachycardia and inhibit the growth of infantile hemangioma, as an alternative to invasive 
procedures for the treatment of large CAs (17,51). 
Management of large CAs remains, however, a therapeutic challenge (10). 
 
1.2 INFANTILE HEMANGIOMA (IH) 
1.2.1 Introduction 
Infantile hemangioma (IH) is the most common neoplasm of childhood (52,53,54). Its exact 
etiology and pathogenesis remains unclear despite thorough studies and many proposed 
mechanisms (53,55,56). Nevertheless, angiogenesis and in recent studies even vasculogenesis 
are suggested to play an important role in pathogenesis of these lesions (57,58). IHs are 
benign vascular tumors characterized by a predictable clinical course in form of a unique 
ability to involute after rapid proliferation (52,53,59). The initial proliferative phase begins in 
the first 2 weeks of life and lasts 6 to 10 months, when tumor grows rapidly due to an 
excessive proliferation of endothelial cells (52). This is followed by gradual spontaneous 
involution, when proliferation is reduced and apoptosis increases, thus, the growth of the 
lesions slows down and finally stops (52). The involuting phase, with histological fibrosis and 
fat deposition, begins between 6 and 12 months of age and most of tumor regression occurs 
before age of 4 years (53,59). An intermediate phase, between proliferation and involution, 
more likely represents a period of temporary balance between cellular proliferation and 
involution/apoptosis (53). Approximately 50% to 70% of IHs undergo spontaneous 
regression but resolve incompletely, leaving permanent residual skin changes including fibro-
fatty residua, telangiectasia or dyspigmentation (53,59). Only about 10-20% of IH become 
clinically significant and require treatment (52,57,59).  
There are also rare congenital variants of the common infantile hemangioma, with similar 
features, but biologically and behaviorally distinct forms (52,53,54). Congenital 
hemangiomas are fully formed at birth and do not express GLUT1 (52,53,54,60). The rapidly 
involuting congenital hemangiomas (RICH) regress rapidly within the first year of life (7-14 
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months) (52). In contrast, non-involuting congenital hemangiomas (NICH) remain stable 
after birth without growth or regression (52,53). 
 
1.2.2 Incidence 
The estimated incidence of IH is approximately 3-10% of infants (61). About 60-80% of 
IHs occur on the head and neck (52,62). Female infants are more likely to be affected; 
female-to-male ratios varying from 1.4:1 to 3:1 and a significantly higher incidence of IH 
has been reported in Caucasian infants (53,54,59,63). It has been suggested, that low birth 
weight, which is usually related also to prematurity, is the major contributor to an increased 
risk of IH, affecting 22-30% of infants weighing less than 1 kg and with every 500-g 
reduction in birth weight the risk of developing IH increases 25% (53,59,63,64). The 
mechanism, by which fair skin and female neonates show an increased risk of developing 
IH might be related to the higher levels of renin compared with dark skin and male 
neonates (65). An increased level of renin leads to a higher level of angiotensin II within 
the IH, which in turn promotes the endothelial proliferation (65). Increased renin level is 
found also in Caucasians compared with Blacks, premature compared with full-term 
infants, and children compared with adults (65). It could even explain the spontaneous 
involution of IH: the renin levels decrease as children grow older (65). 
Of interest, Kim et al reported correlation between unplanned pregnancies with maternal 
smoking and/or alcohol consumption and increased incidence and severity of IH (66).  
In addition, higher prevalence of IH has been described in relation to several prenatal 
factors including increased maternal age, preeclampsia, multiple gestation, placenta praevia 
and breech presentation. Further, placental abnormalities such as retroplacental hematoma, 
infarction, dilated vascular communications and in association with previous trans-cervical 
chorionic villous sampling or amniocentesis, have also been associated with IH 
development (53,59,65). It has been hypothesized that the common link in these 
associations might be placental hypoxia. (53).   
 
1.2.3 Gross morphology 
Proliferative phase may start as localized macular teleangiectatic erythema, which becomes 
more elevated and rubbery in consistency due to endothelial cell continuous proliferation 
(53). During rapid proliferation, also ulceration of the lesion may arise causing pain and 
scarring (53). In involutive phase IH flattens and shrinks starting from the center outwards 
leaving in most cases behind permanent residual skin changes (53). 
IHs can be classified by location in soft tissue as superficial and deep (53). Superficial IHs 
are red from the surface with little or no subcutaneous component (53). They appear earlier 
20 
and start to involute sooner than deep IHs which reside deep in the subcutaneous tissue and 






Figure 4. Gross morphology of centrally ulcerating infantile hemangioma (A); histology of 
proliferating capillary vessels in infantile hemangioma hem.-eos. 40x. 
 
1.2.4 Microscopic features 
Proliferative and early involutive IHs are usually well-defined, red nodules or plaques (53). 
Regressive lesions are less defined, lighter in color and softer, fibro-fatty in consistency (53). 
During the intermediate phase IHs may show mixture of morphological features of involutive 
and proliferative phases, as the dividing line between proliferation and involution is not 
always sharp (53). Histologically the proliferative phase is characterized by well-
circumscribed but unencapsulated, lobulated lesion of closely packed capillaries lined by 
endothelial cells and pericytes, which are separated by delicate fibrous stroma (53).  During 
this phase, endothelial cells and pericytes proliferate actively; hence, normally configured 
mitotic figures are relatively numerous (53). In involuting phase proliferation of the cells and 
the number of mitotic figures decreases while the amount of apoptotic bodies and masts cells 
increases (53). Further, the lesional capillaries start to vanish; the basement membranes 
hyalinize, may contain apoptotic debris until eventually only loose fibrous or fibro-adipose 
stroma remains, containing isolated “ghost” capillaries with residual, thickened, hyalinized 
rinds of basement membrane material studded with apoptotic debris, but without intact 
endothelial linings (53). Thrombosis or prominent inflammation is not related to regression 
process (53).  
Complementary to clinical history and histological examination the most useful 
immunohistochemical marker in the diagnosis of IH is GLUT1, which shows strong 
expression in IH endothelial cells at all stages of their development and therefore may be 
used as diagnostic tool distinguishing diagnostically challenging variants of IH from other 
vascular proliferations or neoplasms (53,67).  
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Figure 5. Histology of proliferative capillary blood vessels in the IH (A), hem.-eos. 100x; 
GLUT 1 positive staining of endothelial cells in IH, 100x. 
 
 
1.2.5 Molecular background 
IHs occur usually sporadically and their molecular basis is unknown (62). However, the 
occasional reported familial cases of IH and epidemiological studies suggest possible genetic 
background influencing the pathogenesis of the lesions (62). Five families with autosomal-
dominant inheritance of IH have been reported, which allowed the identification of a possible 
locus on 5q31-33 containing three candidate genes (62). Recent studies demonstrate that 
some IH patients carry heterozygous missense mutations in the gene VEGFR2 (Vascular 
endothelial growth factor receptor 2) or TEM8 (tumor endothelial marker-8) (62,68). 
 
1.2.6 Diagnosis 
IH is generally diagnosed by history and clinical appearance, imaging of IH is usually not 
necessary (53,59). However, in cases of uncertain diagnosis, ultrasonography is a reasonable 
initial method revealing a well-circumscribed high-flow mass with possible vascular shunting 
(53,59). Echogenicity of the lesion increases during the involution due to the fat tissue 
replacement (53). Gray-scale ultrasound and color Doppler imaging examination are also first 
line choices for monitoring the response of IH to pharmacological therapy (53). However, 
MRI (magnetic resonance imaging) is more useful modality for evaluating the extent of the 
lesion and the surrounding anatomy (53,59). 
 
1.2.7 Treatment 
IHs have uniquely dynamic lifecycle and many lesions involute completely without 
significant sequelae (69). Approximately 10-20% of patients require clinical intervention 
(52,70,57,59).   Indications for treatment include: 1. IHs causing ulceration, pain and bleeding 
A B 
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2. location in functionally sensitive areas (eyes, airways) and 3. large IHs with significant 
disfigurement (59,69). The treatment is currently pharmacological (beta- adrenergic blockers, 
corticosteroids) or surgical (laser therapy, excision in appropriate cases) (69). The beta- 
blocker propranolol is the first line therapeutic choice in patients without contraindications, 
including hypotension, heart failure, sinus bradycardia, bronchial asthma and hypersensitivity 
(53,59,69,71,72,73). The specific mechanism of propranolol`s effect is unknown but more 
likely is a combination of vasoconstriction, inhibition of angiogenesis and simulation of 
apoptosis (4,53,59,71,72). Propranolol has shown better effect and fewer side effects than 
corticosteroids (74). Corticosteroid therapy can be systemic, topical or intralesional and it 
affects the growth of IH by modifying the pro-angiogenic genes (4,53,69,).  
Laser therapy does not inhibit the proliferation of IHs and is mainly used for lesions with 
non-complete involution and residual teleangiectasia for fading effect (59,69).  
Surgical treatment has limited indications: 1. failed or contraindicated pharmacological 
treatment, 2. anatomical location favorable for resection, 3. high probability that resection 
will be necessary in the future and the scar will be same regardless of timing (53). Surgical 
intervention of IH is suggested after age 4 years when involution of the tumor has completed 
(53). 
 
1.3 PATHOGENETIC THEORIES OF CA AND IH  
The specific etiology and pathogenesis of IHs and CAs are still poorly understood. However, 
indications of the in utero hypoxic status (preeclampsia, multiple gestation, placental 
abnormalities) are reported in cases of CA as well as in cases of IH (3,14,53,75). Also, in 
utero hypoxia is often related to low birth weight, which is known as a major risk factor for 
IH (53). Hypoxia in general is recognized as an important stimulus of activating angio-and 
vasculogenesis through an increased expression of various angiogenetic factors, such as, 
vascular endothelial growth factor (VEGF), placental growth factor (PlGF), Flt-1 (fms related 
tyrosine kinase 1, a high-affinity transmembrane receptor for both PlGF and VEGF), and 
sFlt-1 (a placental-derived, truncated, soluble form of Ftl-1) (14,75,76). Therefore, placental 
hypoxic status or in utero hypoxia may act as a trigger in activation of the leader endothelial 
cells, to initiate a cascade of reactions leading to a proliferation of the endothelial cells and 
development of IH and/or CA (75). Hence, IH most probably develops as a reaction to the 
hypoxic environment and endothelial proliferation is a homeostatic attempt to normalize 
tissue hypoxia (57,78). Furthermore, unlike other vascular proliferations or malformations, 
endothelial cells in IH show cellular expression of GLUT-1, which also is an important 
marker of hypoxia and is upregulated through hypoxia inducible factor-1α (HIF-1α) 
(76,77,78). Consequently, GLUT-1 has been reported to be upregulated within hypoxic zones 
of tumors and also expressed in the placental endothelial tissue (55,76,77,78).  
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The unique self-limited growth of IH including rapid proliferation of endothelial cells, 
followed by apoptosis of the cells and tumor involution may be considered as reflection of the 
life cycle of placenta, in which endothelial cells are also destined to proliferate for only 9 
months (79). Thus, placental origin of the IH as uncontrolled proliferation of embolized cells 
expressing a phenotype similar to that of placental endothelial cells, has been discussed 
(14,79). Moreover, placental origin would explain the unique resemblance in 
immunohistochemical phenotype between vasculature of IH and the placenta, as they share 
several antigens: GLUT1, merosin, Lewis Y antigen, and Fcγ-RIIb, type III iodothyronine 
deiodinase, indoleamine 2,3- deoxygenase, and insulin-like growth factor 2 (IGF2) (54,79). 
Furthermore, similarities have been described also in transciptomes of human placenta and 
IH (55). Genes preferentially expressed in both placenta and IHs were identified, including 
17-β hydroxysteroid dehydrogenase type 2 and tissue factor pathway inhibitor 2 (54,77,79). 
Further, expression of β-human chorionic gonadotropin (hCG) and human placental lactogen 
(hPL) and the absence of the trophoblast markers by endothelium of proliferating but not 
involuting IH, suggest that IH may origin from a placental chorionic villous mesenchymal 
core cells rather than from trophoblast (56,57,80). Thus, placental microvasculature and IH 
share expression of several placenta specific molecular markers and genetic profile, which led 
investigators to the pathogenetic hypothesis that placental damage during early gestation 
results in embolization of ectopic placental cells to fetal cutaneous vessels (55,56). A 
procedure of chorionic villous sampling, usually performed at 11 weeks of gestation, is 
believed to cause disruption of the placenta and possible embolization of placental cells (55). 
Higher risk for IH appears to be limited to the trans-cervically performed procedure, a finding 
that also suggests that precursor cells of IH origin from the placenta (53,55). Molecular 
genetic studies demonstrated no maternal-fetal microchimerism in children with IH 
confirming that the IH cells originate from the fetal part of the placental tissue (81,82). 
Recent studies on the metastatic phenomenon of malignant tumors additionally support the 
idea of placental emboli in fetal circulation and from this angle placenta could be considered 
as a “tumor” and IH as a “metastasis” (83). Several case reports have described a correlation 
between the presence of CA and the incidence of neonatal hemangiomatosis (83). This 
correlation could support the hypothesis of the metastatic niche theory, which proposes that 
CA or placenta itself, secretes substances that prepare the implantation site, where IH occur; 
and that the IH precursor cells come from the placenta as a “benign metastasis” (83,84). First, 
in the preparation of the implantation site, fibronectin is laid down as a consequence of 
interaction between tumor cells and stromal cells (55,83). Thereafter, cell surface 
glycoproteins (CD 133, CD 34, CD 117), VLA4 and VEGFR1- expressing stem cells from 
the bone marrow arrive to the metastatic site (55,83). The next event, once the implantation 
site is complete, is arrival of tumor cells and the expression of VEGFR2 by precursor 
endothelial cells, which leads to angio-and vasculogenesis; expression of VEGFR1 is 
suppressed (55,83). Thus, the metastatic niche to which the tumor cells migrate is prepared 
and ready for tumor proliferation (55). In the case of a possible placental or CA origin of the 
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IH, the fetal side of the placenta or CA would be the source of hemangioma precursor cells 
secreting substances that prepare a site for IH, similar to a metastatic niche (55,83).  
Progenitor cell theory suggests that a common origin of IH and placenta from circulating 
multipotent progenitor cells may explain the link between these two entities (54,55,56). The 
theory holds that IH derive from a somatic mutation in a primitive stem cell, which causes 
further development of these cells towards placental endothelial cells (55,56). It has been 
detected that endothelial progenitor cells express CD133 and CD34, cell surface 
glycoproteins, which were described also in metastatic niche theory as factors helping to 
prepare the metastatic site (55). This finding supports the hypothesis that endothelial 
progenitor cells may play an important role in the development of IH, possibly as precursors 
of the clonal endothelial cells (54,55). Peripheral blood analysis of IH patients has 
demonstrated that endothelial progenitor cells express placenta specific molecular markers 
such as GLUT-1, Fcγ RII and merosin, suggesting that endothelial progenitor cells may 
contribute to the rapid growth of IH (54,55).  
 
1.4 CA AND IH IN PREECLAMPSIA AND MULTIPLE PREGNANCIES 
Multiple gestations have 2-3 times higher incidence of preeclampsia, which is defined as 
gestation related hypertension with proteinuria, compared with singleton gestations 
(85,86,87,88,88,89). Also, the incidence of CA is 2-3 times higher in placentas from multiple 
pregnancies compared with the singleton placentas (12). Poor placentation due to abnormally 
limited superficial decidual cytotrophoblast invasion in the maternal spiral arteries supplying 
the placenta is the first stage in development of preeclampsia (91,92). Consequently, the 
transformation of spiral arteries to high caliber vessels is incomplete, as the myometrial 
segment of the vessels remain narrow, causing hypoperfusion of the placenta (91,92). The 
second stage in development of pre-eclampsia consists of repeated episodes of placental 
hypoxia, leading to an increased production of hypoxia inducible factor-1α (HIF-1α) and 
transforming growth factor-β1 (TGF-β1), increasing the secretion of a splice variant of the 
VEGF receptor sFlt-1 (soluble fms-like tyrosine kinase-1) (91). Recent studies suggest that 
maternal endothelial dysfunction resulting from placental soluble fms-like tyrosine kinase-
1(sFlt1) and soluble endoglin (s-endoglin), two circulating antagonists to vascular endothelial 
growth factor (VEGF) and placental growth factor (PlGF) may be part of a pathogenetic 
pathway in preeclampsia (6,86,90,93,94,95). Women with multiple pregnancies have 
demonstrated elevated levels of circulating sFlt1, s-endoglin and PlGF, and elevated sFlt1 to 
PlGF ratio compared with women with singleton pregnancies (93,94,96), these factors have 
also been discussed as pathogenetic inducers of CA. However, not all women with high sFlt1 
and sFlt1 to PlGF ratio develop preeclampsia, which supports the hypothesis that 
preeclampsia has multifactorial pathogenesis and latter pathway is just one part of the 
complicated mechanism (93,94,95). On the contrary, cigarette smoking is associated with 
lower levels of sFlt1 and decreases the risk for preeclampsia (94,92). Two theories to explain 
the mechanism that leads to a cascade of events to develop preeclampsia in multiple 
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pregnancies have been proposed: 1. Placental hypoperfusion with intrauterine hypoxia, 2. 
Larger placental mass producing more preeclampsia related angiogenic factors (85,94). 
Hypoxia due to reduced placental perfusion has been demonstrated to induce sFlt1 production 
in vitro and in an animal model (85,93). On the other hand, a recent study failed to 
demonstrate correlation between larger placental mass and elevated anti-angiogenic profile in 
multiple compared with singleton pregnancies (93,97). In women with history of 
preeclampsia the subtle anti-angiogenic balance persists, which may explain the association 
of preeclampsia with an increased risk of cardiovascular diseases (93,97). It is unknown if 
elevated anti-angiogenic profile persists also in women with history of multiple pregnancies 
and if that could cause increased risk for cardiovascular diseases in this group as well (93). It 
has been speculated even that anti-angiogenic response may reduce maternal risk for breast 
cancer after multiple pregnancy and preeclampsia (93). 
Clinically, gestational hypertensive disorders including preeclampsia demonstrate much more 
favorable neonatal outcome in multiple compared with singleton gestations (98). An 
explanation to this could be that elevated blood pressure in multiple pregnancies is may be a 
physiologic response to increased demand for blood (oxygen) supply by multiple fetuses 
(98). Accordingly, authors have been speculating that placentas from singleton pregnancies 
may show more pathological changes related to affected blood supply and hypoxia compared 
with placentas from multiple pregnancies, but there are no published studies describing these 
placental changes (98).   
Multiple gestation is considered as a risk factor for increased incidence of IH in several 
studies (61,99). Multiple pregnancy may feasibly cause physical restriction of the placental 
development and poor growth of all fetuses may reflect a general uteroplacental dysfunction 
(100). On the other hand, discordant fetal growth in multiple pregnancies may be result of 
several factors including genetic differences between fetuses, dysfunction of one placenta and 
unequally shared placenta (100). The growth discordance in multiple pregnancies is defined 
as birth weight difference >25% between fetuses (100). In multiple pregnancies, generally 
smaller or sicker neonate is in bigger risk to develop IH. Greco et al, however, found that in 
many discordant twin pairs the larger twin developed IH, which indicates that there are other 
factors than low birth weight playing a role in pathogenesis of IH (99).  
Furthermore, preeclampsia has been described as a prenatal factor possibly associated with 
development of IH (53). However, a recent study by Auger et al failed to demonstrate any 









The overall aim of this thesis was to elucidate the pathogenesis of CAs, more specifically 
whether they are hypoxia related tumor-like-lesions or true tumors and find possible 
differences in the pathogenesis between large and small lesions. Further, to investigate the 
clinical significance of small CAs and assess whether the hypoxic background may be the 
common link between CAs and IHs. 
The specific aim of each study was: 
 
STUDY I 
To study morphological characteristics of CAs and to analyze associations between CAs and 
hypoxia related morphological changes of placenta in singleton and multiple pregnancies. 
STUDY II 
To investigate clinical pregnancy characteristics and neonatal outcome in singleton and 
multiple pregnancies with CA and to explore the clinical significance of these lesions.  
STUDY III 
To examine a possible genetic background of large CAs by investigating large structural 
changes involving gain or loss of genetic material (deletions, duplications) by using array 
comparative genomic hybridization (a-CGH) method.  
STUDY IV 
To explore the epidemiological co-existence of CA and IH and their risk factors in singleton 
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3 MATERIALS AND METHODS 


















Figure 3. Flow chart of population for all four studies. 
 
3.1 IDENTIFICATION OF CASES WITH CA AND CONTROLS WITHOUT CA 
During the period of 1996-2012 15742 placentas, including 2112 (13,4%) from multiple 
pregnancies (2095 twin placentas and 17 triplet placentas), were examined at the Section for 
Perinatal Pathology, Department of Pathology at Karolinska University Hospital, Sweden. 
Placentas were referred for pathological examination according to the regional consensus 
indications and were morphologically examined based on a standardized, detailed protocol.  
CAs were defined as nodular lesions composed of capillary vascular channels surrounded by 
trophoblast (3). One hundred and seventy CAs (from 121 singletons and 49 multiple 
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pregnancies) were identified during the study period, coded as hemangiomas according to the 
Systematized Nomenclature of Medicine (SNOMED). Gross examination data were collected 
from original reports and histological slides were re-reviewed by two perinatal pathologists.  
Controls (242 singleton and 98 multiple placentas) were randomly selected from a cohort of 
3000 placentas without CAs that were referred for morphological examination according to 
the regional consensus indications during the period of 2012-2013 (Figure 3). Controls were 
matched with the cases by the gestational age group and by the outcome of the pregnancy. 
Gestational age was retrieved from medical records and evaluated according to ultrasound 
examinations performed in the beginning of the second trimester.  
 
3.2 PLACENTAL PATHOLOGICAL CHANGES  
The histological variables that have been evaluated in all placentas were villous maturation, 
presence of decidual arteriopathy, infarction, intervillous thrombosis, abruption, fetal 
thrombi, chorioamnionitis and villitis; also, length, insertion site, coiling index and number of 
vessels of the umbilical cord. Morphological criteria for placental pathological changes are 
presented in Table 1. 
CAs were measured and localization, morphological form and presence of multiple or single 
lesions were assessed. Placental weight adequacy to gestational age was assessed according 
to the tables by Pinar H et al (102,103).  
Table 1. Morphological criteria for placental pathological changes. 
Diagnosis Morphological criteria 
Maturation 
Subjective assessment of delayed or accelerated maturation of 
chorionic villi compared with the gestational age 
Infarction Ischemic necrosis of chorionic villi of any size or localization 
Decidual arteriopathy 
Fibrinoid necrosis of maternal vessels with or without acute 
atherosis 
Chorioamnionitis Acute subchorionitis, chorionitis and/or chorioamnionitis 
Vasculitis 
Acute inflammation of vessels in chorionic plate and/or umbilical 
cord 
Villitis Foci of chronic villitis in any size 
Intervillous 
thrombosis 




Insertion up to 1 cm from the edge of the placenta or directly to the 
membranes was defined as the marginal/velamentous 
Umbilical cord coiling 
index 
Normal 0,07-0,30; 
coiling index was not calculated for umbilical cord shorter than 20 
cm or for formalin-fixed placentas 
Abruption Retroplacental hematoma 
Fetal thrombosis 
Thrombosis in chorionic plate and/or stem villous vessels or 
umbilical vessels 
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3.3 MATERNAL CLINICAL CHARACTERISTICS AND NEONATAL OUTCOME 
Maternal baseline characteristics, pregnancy and neonatal outcome data were retrieved from 
original medical records or electronic databases (Obstetrix, TakeCare) for cases with CA.  
Neonatal birth weight adequacy to gestational age was evaluated according to Swedish 
growth charts (mean ± 2SD).  The umbilical artery pulsatility index (PI) was calculated 
automatically by the ultrasound systems according to the method of Gosling et al. (5,104). 
Normal fetal umbilical artery blood flow velocity was classified as BFC 0 and abnormal as 
BFC I–III (105,106,107). Criteria for clinical characteristics are presented in Table 2. 
Table 2. Criteria for clinical characteristics. 
Clinical characteristics Criteria 
Maternal body mass index (BMI) ≥ 25 was considered as overweight 
Preeclampsia Systolic blood pressure ≥140 mmHg or diastolic 
≥90 mmHg with or without proteinuria; HELLP 
Diabetes Fasting plasma glucose ≥ 7.0 mmol/l; Plasma 
glucose ≥ 11.1 mmol/l 2 hours after glycose 
tolerance test 
Prematurity delivery < 37th week of gestation 
Apgar score at 5 min <7 at 5 min was considered as low 
Pulsatility index (PI) PI > mean + 2 SD was classified as abnormal 
Blood flow classes (BFC) BFC 0 – positive diastolic flow, PI ≤ mean + 2 SD; 
BFC I - positive diastolic flow, PI > mean + 2 SD 
and PI ≤ mean + 3 SD; 
BFC II - positive diastolic flow, PI > mean + 3 SD 
and/or absent end diastolic flow; 
BFC III – absent end diastolic flow and/or reversed 
diastolic flow 
 
3.4 GENETIC ANALYSIS OF LARGE CA 
During the period of 2009-2016 fresh frozen tissue from eight large histological confirmed 
CAs and from unaffected tissue of same placenta was collected at the Pathology Department 
of Karolinska University Hospital, Stockholm, Sweden. All placentas were from singleton 
pregnancies, the gestational age varied from 28 to 41 weeks (mean 34.17 ± 4.71) and none of 
the cases had clinically diagnosed preeclampsia. The diameter of the lesions was in the range 
of 4 to 15 cm (mean 8.44 ± 3.7), two CAs showed histologically extensive necrotic and two 
partial degenerative changes. One case was from cohort of 170 CAs described above (Figure 
3). 
The genetic study consisted of array comparative genomic hybridization (a-CGH) using the 
Agilent 2x400K high-definition comparative genomic hybridization microarray (Agilent 
Technologies), including a total of 400000 oligonucleotide probes. The tissue from eight 
large CAs was analyzed in comparison with DNA from unaffected placenta tissue and pooled 
standard control genomic DNA (Promega, Madison, WI, USA), respectively, looking for 
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large unbalanced structural genomic changes (deletions and duplications). The pooled control 
genomic DNA consists of approximately 100 healthy individuals’ DNA (not placenta). 
Comparison with normal placental tissue from the same individual excludes somatic 
chromosomal structural changes and with standard genomic DNA helps us to exclude 
constitutional large structural changes. 
 
3.5 IDENTIFICATION OF IH IN CASES AND CONTROLS 
An informative questionnaire with illustrative photos of IH was sent to 469 mothers (153 
cases with CA and 316 controls) of 323 singleton (104 cases and 219 controls) and 146 
multiple (49 cases and 97 controls) live born neonates registered in Sweden; individuals, 
which were extracted from the same cohort of 170 cases with CA and 340 controls without 
CA (Figure 3.). In total, 323 (68.9%) answers were received, of which 13 parents (4 cases and 
9 controls) chose to be excluded from the study. Thus, in total 310 individuals (66.1%) 
provided their consent and were included to the study. The distribution between cases and 
controls was 96 vs. 214, respectively, and between singleton and multiple pregnancies was 
216 vs. 94, respectively. 
 
3.6 STATISTICAL ANALYSIS 
In study I, CA characteristics and placental morphological changes of 170 placentas with 
CAs compared with the 340 matched controls were analyzed in two groups; placentas from 
singleton and multiple pregnancies; and were compared with the respective control group. In 
study II, maternal characteristics of 170 mothers with CA and neonatal outcomes of related 
221 infants (121 from singleton pregnancy and 100 from multiple pregnancies) were 
analyzed comparingly in singleton and multiple pregnancies; control groups were not 
included. Further, in both studies the characteristics were analyzed in association to the 
diameter of CA.  
In study IV, 310 patients (96 cases and 214 controls) of 216 singleton (64 cases and 152 
controls) and 94 multiple (32 cases and 62 controls) pregnancies were analyzed accordingly: 
singleton compared with multiple gestation, and cases with CA compared with controls.  
Statistical analysis for all studies was performed using the R software version 3.0.3 (R 
Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org/)  
The following tests were used where appropriate: The Pearson’s chi-squared and the 
Fisher’s exact (in case of small sample size) tests were applied to examine the relationship 
of categorical data on contingency table analysis.  The Shapiro-Wilk normality test was 
used to determine whether sample data has been normally distributed. The non-parametric 
tests, Wilcoxon rank-sum and Kruskal-Wallis (in variables with more than two groups) 
applied in the analysis of variables, which were non-normally distributed. Uni- or 
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multivariate logistic regression analysis of data applied to estimate odds ratio (OR) values 
with 95% confidence intervals (CI).  A p value of <0.05 was considered significant for all 
analyses.   
 Study III consisted of two parallel comparison analyses of CA with different controls. One 
analysis found no differences between two compared groups and second analysis revealed 
altogether 48 common CNVs. Thus, statistical analysis was not applicable. 
 
3.7 ETHICAL CONSIDERATIONS AND PERMISSIONS 
The placenta tissue material (paraffin embedded blocks and histological slides) is stored in 
the Department of Pathology according to the Swedish Act on Biobanks (2002:297), and is 
based on patients` informed consent. Ethical permissions are required for using this tissue 
material in research according to the Act concerning the Ethical Review of Research 
involving Humans (2003:460). 
All studies were approved by the Regional Ethical Review Board in Stockholm, Sweden.  
Dnr: 2012/1430-31/1 approved 2012-10-16 (Study I-IV).  
Dnr: 2014/158-32 approved 2014-03-25 (Study I, III).  
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4 RESULTS  
4.1 CA CHARACTERISTICS 
The overall incidence of CAs was 1.08% in our cohort of 15742 placentas. Study I 
demonstrated that the frequency of CA was significantly higher in the group of multiple 
compared with the singleton pregnancies (2.32% vs 0.89%, p<0.0001). Most of the tumors 
showed nodular structure (n=144, 84.70%), were presented as single lesions (n=140, 
82.35%), located subchorially (n=122, 71.76%) and discovered already during the gross 
examination of the placenta (n=95, 55.88%).  Overall, singleton and multiple placenta groups 
showed no statistically significant differences in morphological characteristics of CAs 
(Figure 4).  
 
 
Figure 4. Morphological characteristics of CAs in singleton and multiple placentas. 
 
The diameter of CA ranged from 0.05 cm to 13.5 cm, median (IQR) 1.1 cm (0.5-1.9). The 
smaller median diameter of the CA was associated with small for gestational age (SGA) 
placentas, accelerated chorionic villous maturation, placenta infarctions, decidual arteriopathy 
and absence of fetal thrombosis. Study II showed that in singleton pregnancies the smaller 
median diameter of the CA was related to preeclampsia, whereas multiparity and maternal 
smoking were associated to a larger median diameter of CA. In neonates from singleton 
pregnancies the smaller median diameter of CAs was found in SGA neonates, as well as in 
the group of neonates admitted to the neonatal care unit. On the other hand, in neonates from 
multiple pregnancies no statistical significant associations between any of the studied 
neonatal outcomes and the diameter of the CAs were observed.  In study IV, the diameter of 
CA in cases of co-existence of CA and IH (n=18) ranged from 0.1 to 10 cm, the median 
(IQR) 1.25 cm (0.78-2.48); indicating that the size of CA was not related to the development 
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Array-CGH analysis of eight large CAs in study III detected altogether 48 common 
polymorphic CNVs in eight CA samples (median=5.5 per sample) when compared with 
pooled standard control DNA and none when compared with DNA from unaffected placenta 
from the same individual. All described structural changes (duplications and deletions) were 
found in databases (Database of Genomic Variants, http://dgv.tcag.ca/dgv/app/home) of 
known polymorphisms and classified as benign. No common pathogenic, rare or novel 
structural changes involving gain or loss of genetic material compared with either standard 
control DNA or unaffected placenta DNA were revealed.  
 
4.2  PLACENTAL MORPHOLOGICAL CHARACTERISTICS 
One hundred and seventy placentas with CA included 49 multiple placentas of which 29 were 
dichorionic, 18 monochorionic and 2 trichorionic placentas.  
In singleton placentas with CAs the incidence of infarction (p=0.0000055), decidual 
arteriopathy (p=0.0004), fetal thrombosis (p=0.000035), hypercoiled umbilical cords 
(p=0.0004), large for gestational age (LGA) placentas (p=0.00011), accelerated (p=0.00059) 
and delayed maturation of chorionic villi (p=0.04) was significantly higher compared with 
the control group (Figure 5).  
Multiple placentas with CAs showed significantly higher incidence of fetal thrombosis 
(16.33% vs 4.08%, OR=4.58, p=0.017) in comparison with the control group (Figure 5). 
None of the other assessed variables reach the level of statistical significance.  
 
 
Figure 5. Incidence of hypoxia-related placental changes with statistically significant 
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4.3 MATERNAL BASELINE CHARACTERISTICS 
The gestational age in cases with CAs (n=170) ranged from 20 to 43 weeks, the median 
(IQR) gestational age was 37 weeks (33.25-39); the median (IQR) in singleton pregnancies 
was 36 (33-39) weeks and in multiple pregnancies was 37 (35-38) weeks. The frequency 
distribution between gestational age groups in singleton and multiple pregnancies is presented 
in Figure 6.   
 
 
Figure 6. The frequency distribution between gestational age groups in singleton and 
multiple pregnancies. 
 
Maternal baseline characteristics in singleton and multiple pregnancies demonstrated no 
statistically significant differences between the two studied groups. Maternal age (mean ± 
SD) was 31.3 ± 5.7 years in singleton pregnancies and 33 ± 4.9 years in multiple pregnancies. 
The distribution of maternal baseline characteristics between the studied groups is presented 
in Figure 7. 
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4.4 NEONATAL OUTCOME 
Neonates from singleton compared with multiple pregnancies demonstrated significantly 
more adverse outcome including higher incidence of low 5-minute Apgar score (11.02% vs 
4.04%, OR=3.21, p=0.047), abnormal PI (33.33% vs 16.67%, OR=2.50, p=0.037) and BFC  
1 (33.96% vs 14.49%, OR=3.03, p=0.013). Furthermore, the frequency of stillbirths (10.13% 
vs 3.03%, p=0.057) was also higher in singleton compared with the multiple neonates. The 
incidence of CA was higher in female (n=122, 55.20%) compared with male (n=94, 42.53%) 
neonates. The overview of neonatal outcome characteristics in multiple and singleton 
pregnancies is presented in the Figure 8. 
 
Figure 8. Neonatal outcome characteristics in singleton and multiple pregnancies.  
 
4.5 INCIDENCE OF IH 
The incidence of IH showed no statistically significant differences either between cases with 
CA and controls or between singleton and multiple pregnancies. Overall, 57 cases of IH were 
registered in the cohort of 310 individuals. 
The incidence of IH was higher in female (n=33, 60%) compared with male (n=22, 40%) 
neonates and more females were affected in singleton (n=25, 60.9%) compared with multiple 
(n=8, 57.1%) pregnancies; and in controls (n=23, 62.1%) compared with cases (n=10, 
55.6%). However, none of these differences reached the level of statistical significance. 
The incidence of preeclampsia in our selected, high-risk pregnancy cohort demonstrated 
statistically significant differences between the studied groups. A higher incidence of 
preeclampsia was found in cases compared with controls (n=40, 41.7% vs n=52, 24.3%, 
p=0.002) and in singleton compared with multiple pregnancies (n=72, 33.3% vs n=20, 
21.3%, p=0.034).  However, the incidence of IH was not associated with preeclampsia, since 
there was no statistically significant difference between patients with (n=22, 23.9%) and 
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Further, SGA neonates were significantly more common in cases compared with controls 
(n=51, 53.1% vs n=64, 30.1%, p=0.00012), and in multiple compared with singleton 
pregnancies (n=44, 46.8% vs n=71, 33.0%, p=0.021).  
However, none of the studied characteristics demonstrated statistically significant differences 
in relation to the incidence of IH either between cases with CA and controls or between 
singleton and multiple pregnancies. 
Multivariate logistic regression analysis showed significantly higher incidence of CA in SGA 
neonates and in cases with preeclampsia. However, prematurity was significantly higher in 
controls suggesting that it may have a protective impact on incidence of CAs in our cohort 
(Table 5). On the other hand, prematurity was the only characteristic associated with higher 
incidence of IH (Table 6). 
Table 5. Multivariate logistic regression analysis of risk factors for the development of CA. 
Variables1 with CA (N,%) without CA (N, %) OR(95%CI) 2 P value 
SGA3 51(53.1) 64(30.1) 2.08(1.19 -3.63) 0.010 
Gender(females) 52(54.2) 96(44.9) 1.20(0.70-2.04) 0.495 
Prematurity(yes) 42(43.8) 117(54.7) 0.51(0.29-0.90) 0.021 
Preeclampsia(yes) 40(41.7) 52(24.3) 2.09(1.15-3.79) 0.015 
Pregnancies(multiple) 32(33.3) 62(29.0) 1.36(0.74-2.47) 0.311 
Bold font indicates significant results (p<0.05); 1The references for variables entered into the 
model were as follows: SGA (No SGA); Gender (Males); Prematurity (No Prematurity); 
Preeclampsia (No Preeclampsia); Pregnancies (Single). 2Odds ratio (OR) values with 95% 
confidence intervals (CI); 3SGA- small for gestational age. 
 
Table 6. Multivariate logistic regression analysis of risk factors for the development of IH. 
Variables1 with IH (N,%) without IH (N, %) OR(95%CI) 2 P value 
SGA3 20(35.1) 95(37.7) 0.77(0.38-1.56) 0.484 
Gender(females) 33(60.0) 115(50.4) 1.51(0.81-2.81) 0.187 
Prematurity(yes) 42(73.7) 117(46.2) 3.18(1.61-6.25) 0.00078 
Preeclampsia(yes) 22(38.6) 70(27.7) 1.40(0.70-2.76) 0.330 
Pregnancies(multiple) 16(28.1) 78(30.8) 1.22(0.59-2.52) 0.588 
Cases(CAs) 18(31.6) 78(30.8) 1.16(0.58-2.30) 0.664 
Bold font indicates significant results (p<0.05); 1The references for variables entered into the 
model were as follows: SGA (No SGA); Gender (Males); Prematurity (No Prematurity); 
Preeclampsia (No Preeclampsia); Pregnancies (Single); Controls (without CAs). 2Odds ratio 
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5 DISCUSSION    
5.1 MAIN FINDINGS OF THE STUDY 
The incidence of CA in our population of examined placentas from high-risk pregnancies was 
1.08%, which is in line with previously published data.  
Placentas from multiple pregnancies in our study cohort demonstrated higher incidence of 
CAs compared with singleton placentas, which is in accordance with previous studies. 
Placentas from singleton pregnancies with CAs were more affected by hypoxia associated 
morphological changes compared with placentas from multiple pregnancies. Consequently, 
neonatal outcome characteristics followed the same pattern demonstrating an increased rate 
of adverse neonatal outcome in singleton compared with multiple pregnancies.  
Smaller diameter of CA was related to the higher risk of placental affection by hypoxia 
associated morphological changes, preeclampsia and less favorable neonatal outcome.  Small 
CAs are more likely hypoxic vascular hyperplasias associated with malperfusion of the 
placenta, rather than true tumors. 
Genetic analysis of eight large CAs showed no pathogenic structural abnormalities (deletions 
or duplications) in the genome and no structural genomic variation differences between CA 
and unaffected placenta.  
The incidence of IH in our study cohort was 18%, which is higher than previously reported. 
However, no association between CA, gender, preeclampsia, multiple gestation or small for 












5.2 INTERPRETATION OF FINDINGS 
5.2.1 CA association to hypoxia 
CA is a well circumscribed nodular villous capillary lesion of the placenta occurring more 
frequently in pregnancies at high altitude and in association to preeclampsia and multiple 
gestation (3). Thus, CAs are thought to be hypoxia-associated capillary proliferations 
mediated by several growth factors and related to adverse gestational and environmental 
influences, rather than to be true tumors (1,3). Noteworthy, hypoxia has been reported to be 
the major pathophysiologic factor to control angiogenesis (75).  
Hypoxia-associated placental pathological changes can be caused by several different 
mechanisms including: decreased oxygen pressure at high altitude with secondary maternal 
hypoxemia, maternal anemia with reduced oxygen carrying capacity of the blood, maternal 
smoking, overdistension of the uterus by multiple gestation and increased demand for oxygen 
by multiple fetuses and decidual arteriopathy with insufficient spiral artery remodeling and 
trophoblast invasion in preeclampsia (107,108). Furthermore, hypoxia-related morphological 
changes can be classified as focal (placental infarction, CA) or more global (accelerated 
maturation of chorionic villi). However, the placental hypoxia in clinically diagnosed 
preeclampsia is more likely a focal rather a global tissue injury depending on the number of 
affected maternal uterine arteries (108,109).  
 
5.2.2 Placenta hypoxic changes and neonatal outcome in association to CA 
In our tertiary institution, only highly selected placental material is referred for 
histopathological examination, according to the regional consensus indications. Therefore, all 
our studies (study I-IV) comprise a high-risk pregnancy population with a high incidence of 
preeclampsia (41.32% in singleton and 26.53 % in multiple pregnancies). 
In study I, we have assessed overall fourteen different morphological hypoxia associated 
changes of the placenta, seven of which showed statistically significant differences between 
cases and controls in singleton placentas. Decidual arteriopathy, accelerated maturation of 
chorionic villi and infarctions are the morphological indicators of the uteroplacental 
malperfusion and often related to the clinically diagnosed preeclampsia, reflecting a 
decreased intake of oxygen from the intervillous space (108). On the other hand, large for 
gestational age placentas and delayed maturation of chorionic villi, which were also 
associated with an increased risk for CAs in singleton placentas, are morphological 
indications for maternal diabetes mellitus, a status related to intrauterine hypoxia as well 
(108). Moreover, villous hypomaturity has been reported to be associated with increased risk 
of fetal fatality (3,108). Hypercoiling of umbilical cord has been described in relation to 
delayed maturation of chorionic villi and reduced number of villous vasculosyncytial 
membranes, which are morphological features for placental hypoxia (108). In addition, 
abnormal coiling of the umbilical cord may be related to vascular thrombosis in the chorionic 
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plate (110). The frequency of fetal thrombosis in study I was significantly higher in both the 
singleton and multiple placentas with CAs compared with the controls. Further analysis 
revealed that the incidence of fetal thrombosis was associated with larger diameter of CAs, 
which may be explained by the mechanical compression of the vessels in the chorionic plate 
by the larger tumors, thus fetal thrombosis could be secondary to large CA. Moreover, Das et 
al have speculated that large CAs could even produce prothrombotic factors resulting in fetal 
thrombosis (111). 
Based on study I, smaller diameter of CAs was associated with hypoxia related placental 
changes indicating malperfusion of the placenta. Similarly, in study II preeclampsia and 
small for gestational age (SGA) neonates in singleton pregnancies were associated to smaller 
CAs. Accordingly, we hypothesized that small CAs could be considered as hypoxic vascular 
hyperplasias induced often by preeclampsia rather than true tumors. Hence, the recognition of 
CAs as potential morphologic indicator of placental hypoxia and/or preeclampsia could be a 
valuable information for clinical placental diagnostics. 
In study I, placentas from multiple pregnancies with CAs were less affected by hypoxia 
associated changes than singleton placentas with CAs compared with controls. Accordingly, 
we speculated that the low incidence of hypoxia-associated placental changes in multiple 
pregnancies could be explained by the circumstance that multiple pregnancies per se with 
increased demand for oxygen from multiple fetuses are associated with better adaptation to 
the placental tissue hypoxia. This speculation may be further supported by our observation 
from study II that in singleton pregnancies CAs seem to be associated with an increased 
distal placental resistance showing abnormal blood flow velocity waveforms in the umbilical 
artery, while in multiple pregnancies such phenomenon is less common.   
In study II, neonates from multiple pregnancies with CAs demonstrated a much more 
favorable outcome compared with neonates from singleton pregnancies with CAs. 
Accordingly, they showed lower incidence of low 5-minute Apgar score, stillbirths, 
pathological PI and BFC ≥1. The latter finding follows the same pattern as described in our 
study I. Furthermore, the frequency of preeclampsia was very high in our high-risk 
pregnancy cohort and it has been suggested that due to the increased demand for oxygen and 
nutrients, pregnancy induced hypertensive disorders, including preeclampsia might be related 
to a better fetal blood supply in multiple pregnancies (98,112). Consequently, hypertensive 
disorders of pregnancy might have protective effect against low 5-minute Apgar score and 
might be beneficial for fetal survival in multiple compared with singleton gravidities 
(98,112).  
Noteworthy, placental hypoperfusion resulting to intrauterine hypoxia elevates the levels of 
circulating angiogenic/antiangiogenic factors of placental origin including the soluble fms-
like tyrosine kinase 1 (sFlt-1) and sFlt-1/PlGF ratio (93). Similar alterations in serum levels 
of these factors have been demonstrated in preeclampsia and in multiple pregnancies (86,93). 
Our speculation of placental tissue hypoxia in multiple pregnancies could explain the 
increased level of sFlt-1 and sFlt-1/PlGF ratio in multiple compared with singleton 
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pregnancies without preeclampsia (86,93). The latter might suggest a shared pathogenetic 
mechanisms and/or to reflect an increased hypoxic environment in utero in multiple 
pregnancies as well as in preeclampsia (93).  
 
5.2.3 Genetic background of CA 
The genetic background of CAs is so far poorly elucidated. However, the occasional reports 
of recurrence of CA suggest that genetic factors may play role in the pathogenesis of these 
lesions (11,36,40). Only few case reports, including cytogenetic data of CA can be found in 
the literature and there are no systematic studies on this topic. We designed our study III as a 
pilot study of eight large CAs investigating large unbalanced genetic structural variants 
(deletions and duplications) using a-CGH method. The selected genotyping platform was not 
targeted specifically at genes within the angio/vasculogenetic pathways but included 180000 
probes and covered the entire genome, as well as targeted 1989 specific genes including 
VEGFA, TGFβ family and PIGF.  
Vascular anomalies including hemangiomas are a heterogenous group of lesions and 
causative mutations have been described in genes encoding proteins involved in the 
angiogenesis signaling pathways (113). Although the specific genetic etiology in most 
vascular anomalies is still unknown, the identification of putative genes related to these 
lesions, could provide a better understanding of their pathogenesis (113). Approximately 30 
different genes have been reported in the literature so far in association with vascular 
anomalies including hemangiomas, which emphasizes that different genetic mutations can 
cause the same vascular anomaly (allelic heterogeneity), a single gene mutation can be 
related to more than one different vascular anomaly (phenotypic heterogeneity), and multiple 
genes can be associated with clinically similar vascular anomalies (locus heterogeneity) 
(113). 
We investigated the possible genetic contribution to development of large CAs and failed to 
find any pathogenic large genetic changes (duplications and deletions) in our relatively small 
sample size of eight large CAs. This lack of genetic aberrations could support a non-tumorous 
genesis of these lesions. On the other hand, hypoxia-related origin of CAs might explain the 
lack of the presence of pathological genetic aberrations. However, additional genetic studies 
are required to exclude the genetic contribution to development of CAs and to investigate 
further possible hypoxia-related genesis of these lesions.  
  
5.2.4 Placenta theory of IH pathogenesis  
The specific etiology of IHs remains still unclear despite of many proposed etiopathogenetic 
mechanisms and hypotheses. The theory of placental origin is based on several similarities on 
the level of cell surface markers and transcriptome shared by endothelial cells of IH and 
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placental microvasculature (56,57,58,79). Accordingly, the placenta theory of pathogenetic 
mechanism of IH hypothesizes that possible placenta tissue damage during gestation results 
in embolization of ectopic placental endothelial cells to the fetal circulation and these cells 
start proliferating in the areas with hypoxic conditions (16,82). Tissue hypoxia is a powerful 
inducer of angio- and vasculogenesis through an increased expression of angiogenic factors 
including VEGF, PlGF, Flt-1 (a high-affinity transmembrane receptor for both PlGF and 
VEGF), and sFlt-1. Therefore, tissue hypoxic status or in utero hypoxia could act as an 
impulse to trigger the principal endothelial cells and initiate a cascade of reactions causing the 
proliferation of endothelial cells and subsequent formation of IH and/or CA (14,75,82).  
 
5.2.5 Incidence of IH in association to CA 
IH and CA share several risk factors, which are often related to hypoxic influence. An 
increased incidence of IH and CA has been reported in association with higher maternal age, 
preeclampsia, fetal female sex, prematurity and multiple gestation (3,14,61). In addition, 
higher risk for IH is related to low birth weight and Caucasian race (61).  
Study IV did not demonstrate any significant correlations between CA, preeclampsia, SGA 
neonates or multiple gestations and increased risk of IH. Even multivariate logistic regression 
analysis revealed significantly higher risk of IH only in cases of prematurity. On the other 
hand, our study cohort consisted of high risk pregnancies and therefore results may not be 
generalized to the whole population. Female neonates in our cohort showed slightly higher 
incidence of developing IH compared with males, but the difference did not reach the level of 
statistical significance. The mechanism, by which female neonates are more often affected by 
IH is suggested to be associated with the higher levels of renin compared with male neonates 
(65). An increased level of renin induces a higher level of angiotensin II, which in turn is an 
activator of the endothelial cell proliferation (65). Same mechanism could explain an 
increased incidence of IH in Caucasians compared with Blacks, premature compared with 
full-term infants, and children compared with adults (65). Even the spontaneous involution of 
IH could be explained by the latter mechanism: the renin levels decrease, as children grow 
older (65). Nevertheless, our study was based on the informative questionnaire answered by 
the parents. Accordingly, we did not go through medical records of the individuals to confirm 
the diagnosis of IH clinically or to collected the information about renin levels for patients. 
Therefore, our study did not include information about renin levels of the individuals and 






5.3 METHODOLOGICAL CONSIDERATIONS 
To the best of our knowledge, it is the largest cohort of CAs reported to the literature so far. 
Retrospective design of studies I, II sets limits on a collection of the data as it is impossible 
to re-examine the placenta macroscopically or study patients according to the designed 
protocol. There is no possibility for additional clinical tests or complementary tissue samples 
from the placenta; investigator is dependent on existing data which is a major disadvantage of 
a retrospective study design.  
Our study cohort originates from tertiary referral center and in our institution only selected 
placentas are referred for a morphological examination, according to the regional consensus 
indications. Therefore, the results of study I and II reflect high-risk pregnancies.  
Recruitment of controls in placental material is always problematic as placental normal 
morphology is changing during gestational weeks, thus healthy term placentas would not 
reflect placental morphological changes in different developmental stage and would therefore 
be suboptimal in a role of controls. An ideal control group would contain healthy placentas 
from gestational age matched with cases; however, recruitment of such a control group is 
unachievable as cases in our study were ranged from gestational week 20 to 43. In study I, 
for morphological analysis, we decided to use control group matched with cases by 
gestational age group and pregnancy outcome. Controls without CA originate also from our 
selected placenta population. In study II, we decided not to use controls or reference material 
to compare since the study comprises a selected, high-risk pregnancy cohort with a high 
incidence of preeclampsia and therefore comparison with a normal reference group would 
have been of limited value. Study II was meticulously designed to assess the differences in 
clinical outcomes between multiple and singleton pregnancies with CA and to further 
elucidate the related neonatal outcomes. In study IV we decided to use our, by gestational 
age matched, controls and not to use healthy term controls as gestational age and prematurity 
were also important variables to analyze. Based on ethical considerations and predictable 
clinical course of IH only live born neonates were included to the study. 
In studies I and II we have considered even distinguishing between the different types of 
multiple gestations (di/trichorionic and monochorionic) to analyze the influence of different 
vascular patterns in different types of placentas, despite a relatively small group of 
observations (n=49). However, the number of the observations in subgroups ended up very 
small and unequally distributed, thus further analysis might undermine the reliability of 
findings (positive or negative results). Consequently, we decided not to proceed further with 
latter analysis.  
In statistical analysis, we have used median value, instead of mean value, and the inter-
quartile range (IQR) is shown instead of the standard deviation (SD) for the diameter of 
CA, gestational age and BMI because the respective variables were determined to have 
non-normal distributions. Consequently, non-parametric tests (Wilcoxon rank-sum and 
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Kruskal-Wallis) were applied in our study to assess the relationship between the diameter 
of CAs and the studied characteristics, where appropriate.   
 For study III, fresh frozen tissue material was collected only from large CAs since from 
small or microscopic CA fresh frozen tissue cannot be collected as the diagnosis is mostly 
confirmed only after careful microscopic examination. Analysis of large CAs was expected to 
be challenging because of degenerative changes (i.e. necrosis, fibrosis, hyalinization and 
calcifications) of the tissue, which often are extensive in these lesions. However, the frozen 
tissue for genetic analysis was collected from macroscopically preserved areas of lesions. 
Based on results of our study, all analyzed CAs showed similar pattern of common CNVs. 
Accordingly, degenerative tissue changes did not play substantial role in the results of our 
analysis.  
The limitation of study III was the relatively small sample size. Large CAs are rare lesions 
and to collect larger sample set would take additional years. Moreover, only one area from 
CAs and unaffected placenta was analyzed. In future, should be considered to collect 
multiple biopsies from both locations to cover all/as many as possible different tissue 
changes. Also, our chosen method (a-CGH) cannot detect smaller (<30 kb) genomic 
alterations and, inherently to the method, cannot identify balanced structural chromosomal 
changes and more likely fail to detect mosaicism. Therefore, additional genetic studies are 
required to assess the genetic contribution in genesis of CAs.   
 A high incidence of IH (18.4%) in study IV could be explained by a selection bias of our 
study design, which was based on an information from parents and not from clinical records. 
Accordingly, parents whose children had history of IH probably were more interested in the 
topic and for this reason more engaged to participate in the study. Furthermore, the incidence 
of IH might be also higher in our study than in medical records since it was reported directly 
by parents and not confirmed clinically; parents might have recorded more IH cases, even 
those, which did not require clinical attention.  Thus, in our study parental memory has been 










6 CONCLUSIONS   
Study I explored the association of CAs with several morphological placental changes in 
the largest cohort of CAs reported in the literature so far. The analysis of data from study I 
confirm that the incidence of CAs is 2.6 times higher in placentas from multiple compared 
with singleton pregnancies. Furthermore, we demonstrated that CAs were associated with 
an increased rate of hypoxia related placental changes in singleton placentas which supports 
the hypothesis of a hypoxia-driven origin of CAs.  
Study II showed a much more favorable neonatal outcome in multiple compared with 
singleton pregnancies with placental CAs, which might reflect an increased demand of 
oxygen from multiple fetuses and a consequential adaptation to the placental hypoxia per se 
in this group. In addition, our finding of an increased rate of an adverse neonatal outcome in 
singleton compared with multiple pregnancies is in line with our results from study I.  
The high incidence of preeclampsia in both singleton and multiple pregnancy groups, reflects 
a high-risk status of our study cohort. Contrary to the literature, preeclampsia was more 
common in our singleton rather to multiple pregnancy group. Remarkably, the high incidence 
(5-8 times higher than in general population) of preeclampsia in the cohort of CAs might lead 
us to identify these lesions as a potential morphologic indicator of placental hypoxia, which 
in turn could be a valuable information for morphologic placental diagnostics and in clinical 
approach of CAs. 
Study III as a pilot study investigated the genetic background of CAs by analyzing structural 
variations (duplications and deletions) in the genome of eight large CAs. The current analysis 
failed to demonstrate any pathogenic chromosomal structural abnormalities in the CA 
genome and to reveal any genetic structural differences when compared with control 
placenta. This lack of findings could support a non-tumorous origin of these lesions, thus 
contribute indirectly to the hypothesis of hypoxia-driven genesis of CAs. However, additional 
genetic studies are required to fully explore the role of genetic factor in the development of 
CAs. 
Study IV showed that in our cohort of 310 patients, the co-occurrence of CA and IH was 
present in 18 cases. However, we failed to confirm an increased incidence of IH in cases of 
CA, multiple pregnancies or preeclampsia described in the literature. According to study 
IV, an increased incidence of CA was related to the preeclampsia and small for gestational 
age birth weight, whereas prematurity was the only characteristic associated with higher 
incidence of IH. Consequently, the presence of CA in the placenta is not increasing the risk 
to develop IH, although the latter observation is not excluding the hypothesis of placental 
origin of IH. 
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7 FUTURE PERSPECTIVES  
The specific etiology and clinical significance of CAs is still unclear and the research on CAs 
is mostly limited by case reports in the scientific literature. A better understanding of 
etiological factors of CAs would help us to evaluate more precisely also the clinical 
significance of these lesions, therefore more systematic studies in this field would be highly 
appreciated. 
The current advance technology of using whole genome sequencing (WGS) could be a 
powerful tool to provide novel insights in the pathogenesis of CAs. Consequently, we have 
proceeded with genetic analysis of eight large CAs using the WGS method and this has 
given us a large amount of unique data to continue working with. WGS analysis provides 
us with the capability to discover smaller (<30 kb) structural variations in the human 
genome, including deletions, duplications and inversions; as well as to study single 
nucleotide variations. Of interest, we could proceed with pathway based gene analysis 
including, putative genes, which provide causal risk for vascular anomalies and genes that 
are related to hypoxia status.  
In our clinical material of multiple placentas, which were perfused with colors for 
investigating vascular anastomosis we have noticed that CAs are apparently supplied in some 
cases by umbilical artery, whereas in other cases from umbilical vein circulation. As a future 
prospect, it would be interesting to investigate to which circulation the feeding vessels belong 
by perfusing the placentas containing CA with colors through umbilical vessels. 
Our study IV was based only on an informative questionnaire, which was answered by 
parents we have not had access to medical records of patients to confirm the diagnosis of IH 
or collect clinical data. However, would be interesting to design a clinical prospective study 
of IH patients with clinically confirmed diagnosis and additional information of renin levels. 
The measurements of renin level are not included in the routine clinical approach of these 
patients; thus, the study should be with a prospective character. 
In addition, the pathogenesis of CAs and IHs could be explored further by comparing the 
immunohistochemical expression of several hypoxia related or angiogenetic factors ((HIF-1α, 
TGF-β1, VEGF, PlGF, Flt-1 and sFlt-1) on paraffin embedded material of these two lesions. 
Furthermore, to study retrospectively, where possible, placentas of patients with IH in 







8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Bakgrund: Chorangiom (CA) är den vanligaste tumör-liknande förändring i moderkakan 
(placenta), men dess uppkomstmekanismer är ofullständigt klarlagda och eventuella 
genetiska faktorer är outforskade. CA består av fetala kapillärer och finns i c: a 0.5 – 1% av 
alla placentor. I placentan observeras de oftast inom de minst väl syresatta områden. 
Dessutom är CA vanligare i graviditeter på hög höjd samt i samband med 
havandeskapsförgiftning (preeklampsi). Dessa observationer har lett till hypotesen att CA är 
kärlproliferationer associerade till kronisk syrebrist (hypoxi) i placenta snarare än äkta 
tumörformer. CA kan vara små (<1cm) och upptäckts då oftast accidentellt vid patologisk 
undersökning av placenta. Alternativt är CA stora (> 5–8 cm) och kan i dessa fall upptäckas 
vid prenatal ultraljudsundersökning och eventuellt behandlas. De stora CA är förknippade 
med allvarliga graviditetskomplikationer, såsom fosterdöd, tillväxthämning, fetal hydrops 
mm. Infantilt hemangiom (IH) är den vanligaste tumörformen under barndom. IH är i likhet 
med CA kapillära proliferationer och karaktäriseras av ett till stor del förutsägbart 
naturalförlopp, där majoriteten genomgår spontan regress oftast innan 4 års åldern. Orsaken 
till IH är inte känd men enligt en teori har IH dess ursprung i endotelceller från placentan som 
implanterar sig hos det nyfödda barnet, i likhet med en benign ”tumörmetastas”. 
Frågeställning: Syftet med avhandling var att försöka klargöra uppkomstmekanismer för 
CA, mer specifikt att försöka besvara frågan huruvida CA är tumörliknande förändringar 
relaterade till syrebrist i placenta eller äkta tumörer. I samband med det ville vi belysa om det 
skulle kunna finnas genetiska faktorer som bidrar till genes av CA. Vi ville också undersöka 
eventuella skillnader mellan små och stora CA och utforska den kliniska betydelsen av de 
mindre CA. Vidare, vi ville utreda eventuella samband mellan CA och IH. 
Material och Metodik: Vårt studiematerial utgjordes av 170 fall av CA (121 från singelbörd 
och 49 från flerbörd) som identifierades genom särskild kodning i Avd. för Patologins, 
Karolinska Huddinge, databas 1996–2012. Under denna period undersöktes totalt 15742 
placentor enligt consensus definierade kliniska indikationer. Kontrollplacentor (340) 
rekryterades slumpmässigt från en kohort av 3000 placentor från 2012–2013 och var 
matchade för gestationslängd och graviditets utgång. Samtliga fall och kontroller genomgick 
noggrann histopatologisk analys av två perinatalpatologer. Makroskopiska data hämtades från 
ursprungsrapporter. I analysen undersöktes storlek, lokalisation och histologisk typ av CA 
samt övriga patologiska drag i placenta, såsom storlek, villusmognad och förekomst av 
infarkter, intervillösa tromber, avlossning, fetala tromber, tecken till akut eller kronisk 
inflammation samt patologi av navelsträngen. Maternella basdata och information om 
graviditet och neonatal utgång extraherades från elektroniska databaser (Obstetrix, Take 
Care). Genetisk analys genomfördes i en subgrupp av 8 stora CA där färskfrusen CA-vävnad 
var tillvaratagen. Vi använde s.k. array genomic hybridisation för att jämföra DNA från CA 
med DNA från frisk placentavävnad från samma patient samt med sammanslaget genomiskt 
DNA från c: a 100 friska individer (inte placenta). Metoden detekterar strukturella 
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kromosomavvikelser > 30 kb.  För att undersökta samband mellan CA och IH använde vi oss 
av ett informativt frågeformulär som inkluderade illustrativa foton av IH. Frågeformuläret 
skickades till 469 mödrar, 153 från fall med CA och 316 kontroller. Statistisk analys 
genomfördes i studier I, II och IV med olika lämpliga metoder inklusive uni- och multivariat 
logistisk regressionsanalys. Etiktillstånd har erhållits för samtliga studier. 
Resultat/slutsatser: 
Studie I: Frekvensen av CA i vår kohort var signifikant högre i flerbörd-  jämfört med 
enkelbördgrupp (2.32 respektive 0.89%). Enkelbördplacentor med CA visade ökad frekvens 
av hypoxi-relaterade förändringar, såsom acceleration i villusutmognad, infarkter, arteriopathi 
i decidua, fetal trombos och hypercoiling (tvinning) i navelsträngen. I flerbördplacentor fann 
vi en signifikant association mellan CA och fetal trombos. För övrigt var histopatologiska 
drag av CA likartade i enkelbörd- och flerbördplacentor. Frånvaro av samband mellan 
hypoxitecken och CA i flerbörd kan indikera att dessa placentor härbärgerar ett inbördes 
hypoxiskt tillstånd som leder till CA uppkomst. 
Studie II: Vår analys av 121 enkelbörd- och 49 flerbörd (motsvarande 100 nyfödda barn) 
placentor med CA visade mycket hög frekvens av preeklampsi i båda grupper. I 
enkelbördplacentor var förekomst av små CA associerad till maternell preeklampsi och av 
stora CA till multiparitet och rökning under graviditet. I enkelbördplacentor fann vi ett starkt 
samband mellan små CA och litenhet vid födseln samt till behov av neonatal intensivvård. 
Frekvensen av låg APGAR score vid 7 minuter, abnorm pulsatilitetsindex och abnorm 
blodflödesklass var signifikant högre i enkelbörd jämfört med flerbörd. Våra resultat tyder på 
att förekomst av CA i placenta kan utgöra en värdefull klinisk-patologisk markör för 
preeklampsi. Vidare, den gynnsammare neonatalutgång i flerbörd med CA kan avspegla en 
effektivare adaptiv mekanism mot kronisk syrebrist i dessa placentor. 
Genetisk analys av 8 stora CA (studie III) visade inga stora strukturella kromosomavvikelser 
(deletioner, duplikationer) i CA-vävnad med array-metoden. Analysen var däremot inte 
specifikt riktad mot gener involverade i angiogenes/vaskulogenes och kan inte heller 
detektera balanserade eller mosaikförändringar. Resultatet talar emot hypotesen att CA är en 
”äkta” tumörform, men vidare helgenomstudier måste bekräfta detta och utesluta eventuellt 
bidrag av mindre strukturella genavvikelser i uppkomst av CA. 
Vårt frågeformulär i studie IV besvarades va totalt 310 mödrar med svarsfrekvens 66.1%. Vi 
kunde inte finna någon skillnad i frekvens av IH mellan fall och kontroller eller mellan enkel- 
och flerbörd. Frekvensen av IH i vårt material var relativt hög (kring 18%), vilket kan 
förmodligen förklaras av att förekomst av IH var självrapporterad från föräldrar och inte 
medicinskt verifierad. Vidare, vi kunde inte finna några signifikanta skillnader i frekvens av 
IH hos nyfödda från graviditet med eller utan preeklampsi och inte heller mellan enkel- och 
flerbörd. Våra resultat ifrågasätter den tidigare framlagda hypotesen om ett enkelt 
patogenetiskt samband mellan CA och IH. 
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